Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America (LATINO Lung)

Latin American Cooperative Oncology Group (LACOG)

Status: Completed

Conditions: Lung Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04227457

LACOG 0116

Details and patient eligibility

About

To describe the overall survival of advanced NSCLC in Latin America.

Full description

• To describe demographic and socioeconomic characteristics of patients newly diagnosed with advanced NSCLC
• To describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced NSCLC
• To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC
• To describe treatment responses, progression and survival times.
• To describe reasons for treatment discontinuation
• To identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival;
• To define the patient experience of advanced NSCLC and identify unmet needs in their diagnose and treatment.

Enrollment: 700 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Patients aged 18 years or older;

2. Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time);

3. Histologically or cytologically confirmed advanced NSCLC:

   1. Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery);
   2. Stage IV metastatic disease (de novo or distant relapse)

4. Any NSCLC histological subtype and molecular mutation;

5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;

6. Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care;

7. Access to patient medical chart for data collection;

8. Willing and able to provide written informed consent and privacy authorization for the release of personal health information.